Explanipedia

Substitution of ifosfamide for cyclophosphamide in the TI-CE regimen: pharmacology and dose justification in a patient with refractory metastatic germ-cell tumor post-nephrectomy—A case report Open

Lotte M. G. Hulskotte, Loek A. W. de Jong, Alwin D. R. Huitema, Joost Sijm, Ingrid M.E. Desar , et al. · 2025

Background High-dose chemotherapy (HDCT) combined with autologous stem cell transplantation (ASCT) rescue is an effective treatment option for relapsed or refractory germ-cell tumors. The TI-CE regimen, consisting of paclitaxel and ifosfam…

Patients in Clinical Trials are Sub‐Optimally Protected for Drug–Drug Interactions: A Call for Action Open

David M. Burger, Loek A. W. de Jong, Daphne van Dijk, Catherijne A. J. Knibbe, Rob ter Heine , et al. · 2024

Contains fulltext : 320576.pdf (Publisher’s version ) (Open Access)

High-dose short-term osimertinib treatment is effective in patient-derived metastatic colorectal cancer organoids Open

Kirti K. Iyer, Dennis Poel, Anne Miggelenbrink, Wouter Kerkhof, Jorien B.E. Janssen , et al. · 2024

Background Most tyrosine kinase inhibitors (TKIs) have failed in clinical trials for metastatic colorectal cancer (mCRC). To leverage the additional lower-affinity targets that most TKIs have, high-dose regimens that trigger efficacy are e…

Cerebrospinal Fluid Concentration of the RET Inhibitor Pralsetinib: A Case Report Open

Loek A. W. de Jong, Rolf W. Sparidans, Michel M. van den Heuvel · 2023

Introduction: Pralsetinib is used to treat metastatic RET fusion-positive non-small cell lung cancer. Preclinical studies of pralsetinib have shown blood-brain barrier (BBB) penetration and intracranial activity. The intracra…

Effect of Aprepitant on Etoposide Pharmacokinetics in Patients with Testicular Cancer: A Pharmacokinetic Study to Determine the Absence of a Clinically Relevant Interaction Open

J.J.T.W.A. Strik, Loek A. W. de Jong, Joost Sijm, Ingrid M.E. Desar, Nielka P. van Erp · 2023

All patients treated with anticancer agents should receive the most effective anti‐emetic regimen. Anti‐emetic guidelines provide recommendations but do not take into account possible drug–drug interactions between anti‐emetics and antican…

Measuring Tumour Imatinib Concentrations in Gastrointestinal Stromal Tumours: Relevant or Redundant? Open

Eline L. Giraud, Loek A. W. de Jong, Erik van den Hombergh, Suzanne E. J. Kaal, Nielka P. van Erp , et al. · 2023

Imatinib plasma trough concentrations are associated with efficacy for patients treated for advanced or metastatic KIT-positive gastrointestinal stromal tumours (GISTs). This relationship has not been studied for patients treated in the ne…

High-dose short-term osimertinib treatment is effective in patient-derived metastatic colorectal cancer organoids Open

Kirti K. Iyer, Dennis Poel, Anne Miggelenbrink, Wouter Kerkhof, Jorien B.E. Janssen , et al. · 2023

Background Despite major interest in tyrosine kinase inhibitors (TKIs) as a treatment option for metastatic colorectal cancer (mCRC), almost all TKIs tested for mCRC fail in early-phase clinical trials. Although showing specific target inh…

Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer Open

Loek A. W. de Jong, Marie Lambert, Nielka P. van Erp, Lukas de Vries, Étienne Chatelut , et al. · 2023

Purpose To determine the systemic exposure to cisplatin and paclitaxel after adjuvant intraperitoneal administration in patients with advanced ovarian cancer who underwent primary debulking surgery. This could provide an explanation for th…

Correction to: Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin‑based HIPEC: results of the GUTOX study Open

Loek A. W. de Jong, Fortuné M.K. Elekonawo, Marie Lambert, Jan Marie de Gooyer, Henk M.W. Verheul , et al. · 2022

all results that were expressed as platinum concentration. The reported results were incorrectly labelled as total and free platinum concentrations, whereas they correspond to total and free oxaliplatin concentrations. This applies to the …

Pressurized Intraperitoneal Aerosol Chemotherapy: The Road from Promise to Proof Open

Loek A. W. de Jong, Nielka P. van Erp, Lana Bijelić · 2021

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is an innovative drug delivery technique invented to be used for the treatment of peritoneal metastasis. Its application gained popularity over the past years. Several prospective cl…

Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin-based HIPEC: results of the GUTOX study Open

Loek A. W. de Jong, Fortuné M.K. Elekonawo, Marie Lambert, Jan Marie de Gooyer, Henk M.W. Verheul , et al. · 2020

Effect of intraperitoneal chemotherapy concentration on morbidity and survival Open

Fortuné M.K. Elekonawo, W J van Eden, Willemijn Y. van der Plas, Roos S. G. Ewalds, Loek A. W. de Jong , et al. · 2020

Background Selected patients with colorectal peritoneal metastases are treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The concentration of intraperitoneal chemotherapy reflects the administe…

Reply to ‘Hyperthermic intraperitoneal chemotherapy with oxaliplatin—Still not standard of care for patients with colorectal peritoneal metastases’ by Julianov and Saroglu Open

Loek A. W. de Jong, Nielka P. van Erp · 2019

\n Contains fulltext :\n 208828.pdf (Publisher’s version ) (Closed access)\n

Consecutive antibiotic use in the outpatient setting: an extensive, longitudinal descriptive analysis of antibiotic dispensing data in the Netherlands Open

Loek A. W. de Jong, Paul D. van der Linden, Monique Roukens, E.M.W. van de Garde, Alike W. van der Velden , et al. · 2019

Although the actual reason for a switch is unknown, switch patterns can reveal problems concerning treatment failure and guideline adherence. In general, switch percentages of antibiotics in the Netherlands are low. The data contributes to…

Bone sarcoma during pregnancy: an example of personalized multidisciplinary care Open

Marije E. Weidema, Suzanne E. J. Kaal, Loek A. W. de Jong, Nielka van Erp, Rosemarie Jansen , et al. · 2018

Contains fulltext : 202619.pdf (Publisher’s version ) (Open Access)

Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis: a clinical pharmacological perspective on a surgical procedure Open

Loek A. W. de Jong, Fortuné M.K. Elekonawo, Philip R. de Reuver, André J. A. Bremers, Johannes H.W. de Wilt , et al. · 2018

Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has become the standard of care in the treatment of patients with peritoneal carcinomatosis of colorectal origin. The use of oxaliplatin for HIPEC has ga…

Muscle rupture associated with statin use Open

Corine Ekhart, Loek A. W. de Jong, Liana Martirosyan, Florence van Hunsel · 2016

AIM Statins are used in the treatment of hyperlipidaemia. They are among the most commonly prescribed drugs worldwide. Statins have been linked to musculoskeletal adverse drug reactions. However muscle rupture has not been discussed as an …

Time course, outcome and management of adverse drug reactions associated with metformin from patient’s perspective: a prospective, observational cohort study in the Netherlands Open

Loek A. W. de Jong, Linda Härmark, Eugène van Puijenbroek · 2016

(Es)omeprazole and Discoloration of Regurgitated Gastric Contents in Infants: Worrying for Care-Takers and a Sign of a Reduced Bioavailability Open

Florence van Hunsel, Loek A. W. de Jong, Tjalling W. de Vries · 2016

Early Adolescent Emergence of Reversal Learning Impairments in Isolation-Reared Rats Open

Susan B. Powell, Asma Khan, Jared W. Young, Christine N. Scott, Mahálah R. Buell , et al. · 2015

Cognitive impairments appear early in the progression of schizophrenia, often preceding the symptoms of psychosis. Thus, the systems subserving these functions may be more vulnerable to, and mechanistically linked with, the initial patholo…

Loek A. W. de Jong YOU? Author Swipe